Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Clinical Trial - Protocol # BIA-2093-304

Grants and Contracts Details

StatusFinished
Effective start/end date3/31/11 → 3/31/15

Funding

  • Sunovion Pharmaceuticals Incorporated: $39,127.00